Clinical Trials Insight: 700029120
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 14 Oct 2010
At a glance
- Drugs Nabiximols (Primary)
- Indications Multiple sclerosis; Muscle spasticity
- Focus Registrational; Therapeutic Use
- Sponsors GW Pharmaceuticals
- 14 Oct 2010 According to an Almirall media release, results from 3 pivotal clinical studies of tetrahydrocannabinol/cannabidiol (Sativex) were presented in a satellite symposium at the 26th annual congress of the ECTRIMS.
- 12 Sep 2009 Results presented at the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS).
- 09 Sep 2009 Primary endpoint 'Improvement in symptoms' has been met.